Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: The first three years

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages 1-

  Wabe, Nasir ^a   Sorich, Michael J ^a,b   Wechalekar, Mihir D ^b,c   Cleland, Leslie G ^c   McWilliams, Leah ^c   Lee, Anita ^c,d   Spargo, Llewellyn ^c   Metcalf, Robert G ^c   Hall, Cindy ^c   Proudman, Susanna M ^c,d   Wiese, Michael D ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; METHOTREXATE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT;

ABDOMINAL PAIN; ACCOUNTING; ADULT; AGED; ANOREXIA; ARTICLE; BODY MASS; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HELPLESSNESS; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUSCLE CRAMP; NAUSEA; PHYSICIAN; PREVALENCE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; VOMITING; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; PRACTICE GUIDELINE; REMISSION; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925740332     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0562-0     Document Type: Article

References (36)

1. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-9.
2. Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, et al. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and Nonsteroidal anti-inflammatory drug Use. Semin Arthritis Rheum. 2007;37:99-111.
3. Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Den Broeder AA, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis. 2012;71:845-50.
4. Vermeer M, Kuper HH, Hoekstra M, Haagsma CJ, Posthumus MD, Brus HL, et al. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum. 2011;63:2865-72.
5. Vermeer M, Kuper HH, Moens HJ, Drossaers-Bakker KW, van der Bijl AE, van Riel PL, et al. Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: Three year results of the DREAM remission induction cohort. Arthritis Care Res. 2013;65:1219-26.
6. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7.
7. Atar D, Birkeland KI, Uhlig T. 'Treat to target': moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis. Ann Rheum Dis. 2010;69:629-30.
8. Tymms K, Zochling J, Scott J, Bird P, Burnet S, de Jager J, et al. Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity. Arthritis Care Res. 2014;66:190-6.
9. Vermeer M, Kuper HH, Bernelot Moens HJ, Hoekstra M, Posthumus MD, van Riel PL, et al. Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Res Ther. 2012;14:R254.
10. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376:1094-108.
11. Wolfe F, Michaud K. Resistance of rheumatoid arthritis patients to changing therapy: Discordance between disease activity and patients' treatment choices. Arthritis Rheum. 2007;56:2135-42.
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
13. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd CO, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum. 2010;2010:2569-81.
14. DeVellis RF, Callahan LF. A brief measure of helplessness in rheumatic disease: the helplessness subscale of the Rheumatology Attitudes Index. J Rheumatol. 1993;20:866-9.
15. Pincus T, Summey JA, Soraci Jr SA, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983;26:1346-53.
16. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68:954-60.
17. de Jong Z, van der Heijde D, McKenna SP, Whalley D. The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br J Rheumatol. 1997;36:878-83.
18. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27:261-3.
19. van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol. 2012;8:337-51.
20. Palmer D, El Miedany Y. Rheumatoid arthritis: recommendations for treat to target. Br J Nurs. 2014;23:310-5.
21. Viester L, Verhagen EA, Oude Hengel KM, Koppes LL, van der Beek AJ, Bongers PM. The relation between body mass index and musculoskeletal symptoms in the working population. BMC Musculoskelet Disord. 2013;14:238.
22. Sullivan PW, Morrato EH, Ghushchyan V, Wyatt HR, Hill JO. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002. Diabetes Care. 2005;28:1599-603.
23. Pincus T. Are patient questionnaire scores as "scientific" as laboratory tests for rheumatology clinical care? Bull NYU Hosp Jt Dis. 2010;68:130-9.
24. Camacho EM, Verstappen SM, Symmons DP. Association between socioeconomic status, learned helplessness, and disease outcome in patients with inflammatory polyarthritis. Arthritis Care Res (Hoboken). 2010;64:1225-32.
25. Nicassio PM, Wallston KA, Callahan LF, Herbert M, Pincus T. The measurement of helplessness in rheumatoid arthritis. The development of the arthritis helplessness index. J Rheumatol. 1985;12:462-7.
26. Bhat AA, DeWalt DA, Zimmer CR, Fried BJ, Callahan LF. The role of helplessness, outcome expectation for exercise and literacy in predicting disability and symptoms in older adults with arthritis. Patient Educ Couns. 2010;81:73-8.
27. Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol. 2002;29:1631-8.
28. Aletaha D, Kapral T, Smolen JS. Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis. 2003;62:482-6.
29. Wiese MD, Alotaibi N, O'Doherty C, Sorich MJ, Suppiah V, Cleland LG, et al. Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis. Pharmacogenomics J. 2014;14:350-5.
30. Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73:62-8.
31. Radner H, Smolen JS, Aletaha D. Impact of comorbidity on physical function in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69:536-41.
32. Kaiser R. Incidence of lymphoma in patients with rheumatoid arthritis: a systematic review of the literature. Clin Lymphoma Myeloma. 2008;8:87-93.
33. van Hulst LT, Kievit W, van Bommel R, van Riel PL, Fraenkel L. Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment. Arthritis Care Res. 2011;63:1407-14.
34. Taylor WJ, Harrison AA, Highton J, Chapman P, Stamp L, Dockerty J, et al. Disease Activity Score 28-ESR bears a similar relationship to treatment decisions across different rheumatologists, but misclassification is too frequent to replace physician judgement. Rheumatology (Oxford). 2008;47:514-8.
35. Lindsay K, Ibrahim G, Sokoll K, Tripathi M, Melsom RD, Helliwell PS. The composite DAS Score is impractical to use in daily practice: evidence that physicians use the objective component of the DAS in decision making. J Clin Rheumatol. 2009;15:223-5.
36. Lee A, Pile K. Disease modifying drugs in adult rheumatoid arthritis. Aust Prescr. 2003;26:36-40.